AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04765995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HZBio1 0.96mg / kg
Description: HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
Study NCT04765995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HZBio1 3mg / kg
Description: HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
Study NCT04765995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HZBio1 6mg / kg
Description: HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
Study NCT04765995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HZBio1 9mg / kg
Description: HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
Study NCT04765995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HZBio1 12mg / kg
Description: HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
Study NCT04765995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered intramuscularly.
Study NCT05735990 — intervention group
Intervention type: DEVICE
Intervention: Intraocular lens
Description: Aspheric hydrophilic acrylic IOL for implantation into the capsular bag
Study NCT05402124 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: acetylsalicylic acid delayed release tablets, 81mg
Description: acetylsalicylic acid delayed release tablets, 81mg taken once per day for 90 days
Study NCT06227442 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: KDIGO criteria of 2010
Description: They are guidelines for the diagnosis, evaluation, and management of chronic kidney disease (CKD). They cover the classification of CKD stages based on glomerular filtration rate and albuminuria, criteria for diagnosing acute kidney injury, and recommendations for managing CKD-related complications.
Study NCT06439628 — intervention group
Intervention type: DRUG
Intervention: Rimegepant
Description: patients take rimegepant to treat migraine attack as needed
Study NCT06443801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: THE GROUP THAT WILL TAKE WEB-BASED BREASTFEEDING EDUCATION IN PREGNANCY
Description: The data of the study will be applied to both groups at the same time. No training will be given to the control group, and web-based breastfeeding training consisting of 4 modules will be given to the experimental group during their pregnancy. As data collection tools; Pregnant data collection form, Postpartum information form, IOWA infant feeding attitude scale, IMDAT scale, Edinburgh depression scale, Breastfeeding motivation scale, Insufficient milk perception scale, Breastfeeding self-efficacy scale and System usability scale will be used. Data collection tools will be applied to women at pregnancy, postpartum 7th day, PP 3rd month and PP 6th month.~Appropriate methods will be used in the evaluation of the data. The significance level will be determined as α=0.05.~The sample of the study consisted of 90 primiparous pregnant women, 45 of whom were in the control and 45 in the experimental group, who met the inclusion criteria.
Study NCT06269016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: expremental pre and post test
Description: effect of strengthening exercise of combined hip strengthening exercises and pelvic floor exercises
Study NCT04782505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1248
Description: Camostat mesylate Tablet from Daewoong
Study NCT05065918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sexual violence and alcohol use harm reduction text message content
Description: The multi-target sexual violence harm reduction and alcohol use intervention will use a similar model to the alcohol use reduction intervention previous developed and implemented. Students will be: 1) queried via TM prior to typical drinking days regarding both alcohol use and SV harm reduction goal setting; 2) provided with goal reminders during drinking period; and 3) assessed for goal attainment and given feedback following drinking episodes. As with the control condition, post-drinking assessment happens weekly on Sundays. Monday thru Saturday participants will randomly receive or not receive one appropriate message pathway from the message library using the pre-determined pathways for messages.
Study NCT05065918 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: alcohol use reduction content
Description: The control condition will be a previously tested TM-delivered alcohol use reduction intervention. Prior to typical drinking occasions, individuals planning a drinking event are prompted to consider committing to a drinking limit goal, i.e.: Would you be willing to set a goal to drink less than X drinks when drinking?. Based on willingness to commit to the goal, a feedback message is provided. During typical drinking periods, individuals receive a goal reminder. Each week, the program provides goal success/failure feedback or drinking quantity feedback. For example, those occasions where an individual committed to a drinking limit goal triggers either messages to reinforce goal successes or reframe goal failures. When an individual did not commit to a drink limit goal, they are provided feedback based on alcohol quantity (e.g. high risk drinking feedback).
Study NCT06106789 — intervention group
Intervention type: DRUG
Intervention: Tobramycin inhalation solution
Description: Tobramycin Inhalation Solution is a yellowish clear liquid, the main ingredient is tobramycin.~Antimicrobial non-nebulized inhalation preparation according to the current clinical situation, mainly polymyxin, amikacin, depending on the specific circumstances of each hospital.
Study NCT06349317 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib
Description: 1. Preoperative IMRT targeting PVTT and intrahepatic tumor lesions with a prescribed dose for 18Gy in 6 fractions delivered by using 6-MV X-rays with a linear accelerator at 5 fractions per week;~2. Perioperative combination of camrelizumab and apatinib Preoperatively, camrelizumab (200mg, every 2 weeks) combined with apatinib (250mg, daily) for 2 cycles (2 weeks as one cycle); Postoperatively, camrelizumab (200mg, every 3 weeks) combined with apatinib (250mg, daily) for 8 cycles (3 weeks as one cycle).
Study NCT05087667 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of Ortholoop cerclage
Description: implantation of Sterile Self Locking Polymer Cerclage System named OrthoLoop to the patient and follow up for 36 months post-intervention
Study NCT05087667 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of Cerclage used in current practice
Description: implantation of Cerclage used in current practice to patients and follow up for 36 months post-intervention
Study NCT04978012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib and Camrelizumab
Description: Maintenance therapy of Fluzoparib and Camrelizumab, until disease progression or intolerable adverse effect.
Study NCT05571553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recommendations and reorientation towards healthcare resources
Description: Phase 1~* After completing the CARE© questionnaire, participants will be given recommendations.~* After the ESOGER© assessment, the participants will be contacted by the Red Cross who will set up the necessary interventions. They will be informed of the results of the assessments made.~Phase 2~* After completing the CARE© questionnaire, participants will be given recommendations.~* If their health status is judged fragile by the CARE© score, and after the ESOGER© assessment, the participants will be contacted by the Red Cross who will set up the necessary interventions. They will be informed of the results of the assessments.~For both phases, after 3 (6) months, the participants of the Control group will benefit from the recommendations following the CARE© assessment done at M3 (M6), and if necessary from the ESOGER© assessment and the Red Cross intervention. Throughout the study, they will continue to receive their conventional care.
Study NCT05217290 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: transtheoretical model
Description: The Transtheoretic Model is a conscious behavior change model and argues that behavior change is a process and that the attempts made in accordance with the change stage of the individual facilitate the change, otherwise resistance to behavior change is developed.
Study NCT05146661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEURESCUE device
Description: The balloon catheter is delivered via the femoral artery, temporarily inflating a soft balloon in the descending to redirect blood flow towards the upper body.
Study NCT06090019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine PICU nursing care for children on mechanical ventilator.
Description: Nursing interns students learned the routine PICU nursing care for the children on mechanical ventilator.
Study NCT06090019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-instructional module for VAP care bundle prevention
Description: Nursing interns students learned about VAP care bundle prevention self-instructional module through assessment, preparation, implementation and evaluation phases.
Study NCT06247488 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participant will receive oral dose of placebo.
Study NCT06247488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone 20 mg
Description: Participant will receive oral dose of oxycodone 20 mg.
Study NCT06247488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone 20 mg
Description: Participant will receive oral dose of oxycodone 20 mg.
Study NCT06247488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GE-IR 200 mg
Description: Participant will receive oral dose of GE-IR 200 mg and oxycodone 20 mg.
Study NCT06247488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GE-IR 450 mg
Description: Participant will receive oral dose of GE-IR 450 mg and oxycodone 20 mg.
Study NCT05212597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sacubitril-valsartan
Description: 50mg\~100mg twice daily
Study NCT05212597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amlodipine-losartan
Description: amlodipine/losartan 2.5/25mg \~ 5/100mg once daily
Study NCT04774783 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy
Description: The TheraTouch LX2 device includes a 9-diode cluster probe which emits a combination of LED and laser light. The cluster probe includes four 650 nm LED diodes capable of delivering a total of 40 mW and five 850 nm laser diodes capable of delivering a total of 1000 mW of power. LLLT will the applied with the cluster probe directly in contact with the subject's skin. LLLT dosages will vary according to the location of the subject's pain and may require multiple applications during a session. Each individual application will typically range from 4-16 Joules.
Study NCT06642363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subjects in the intervention group will receive one capsule containing 10 mg Astaper day made by the Zyest Technology Tarawat Zendig institute in Iran. The dosage of ASX is determined based on the s
Description: Subjects in the intervention group will receive one capsule containing 10 mg Astaper day made by the Zyest Technology Tarawat Zendig institute in Iran. The dosage of ASX is determined based on the s
Study NCT06642363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will take one capsule containing corn starch in a wrapped and covered form and the appearance of ASX supplementation (blinding).
Study NCT06111443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg [Farxiga]
Description: Dapagliflozin 10 mg \[Farxiga\] for 3 months after catheter ablation of atrial fibrillation
Study NCT06019962 — intervention group
Intervention type: DEVICE
Intervention: digital pelvic inclinometer
Description: It is a reliable and valid instrument for measuring pelvic tilt angle
Study NCT05497336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI351
Description: IBI351 is administered orally
Study NCT05497336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab is administered intravenously
Study NCT06478602 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: Performing a colonoscopy with fecal microbiota transplantation at the level of the cecum.
Study NCT05236972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg iv drip Q3W
Study NCT05236972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m² iv drip over 2 hours on day 1, repeated every 21 days.
Study NCT05236972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 1000 mg/m² po twice daily on days 1- 14 repeated every 21 days
Study NCT05220059 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyphenol extract
Description: Single dose
Study NCT05220059 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study NCT05583279 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dialetical Behavioral Therapy for Adolescents
Description: DBT is an evidence-based treatment for individuals with complex clinical presentations, including borderline personality disorder (BPD), suicidality, and NSSI. Standard DBT (which includes individual therapy, skills group, between-session skills coaching, and peer consultation for therapists) is associated with symptom reductions in patients across a variety of domains, including BPD symptoms, SA, NSSI, hospitalizations, and social functioning. DBT focuses on teaching skills (e.g., emotion regulation) and facilitating the replacement of impulsive and/or ineffective behaviors (e.g., NSSI), with more effective/skillful behaviors.
Study NCT05583279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialetical Behavioral Therapy for Adolescents
Description: DBT is an evidence-based treatment for individuals with complex clinical presentations, including borderline personality disorder (BPD), suicidality, and NSSI. Standard DBT (which includes individual therapy, skills group, between-session skills coaching, and peer consultation for therapists) is associated with symptom reductions in patients across a variety of domains, including BPD symptoms, SA, NSSI, hospitalizations, and social functioning. DBT focuses on teaching skills (e.g., emotion regulation) and facilitating the replacement of impulsive and/or ineffective behaviors (e.g., NSSI), with more effective/skillful behaviors.
Study NCT05850897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Masaj
Description: Appropriate position is given to the patients. Thumb and finger movements, patting, rubbing and squeezing techniques are used in foot massage. During training, the active hand applies pressure, while the passive hand uses both hands to support the foot. The intervention begins with rubbing and warming the feet. The duration of the foot warming process is approximately 5 minutes, and after the foot warming maneuvers, the methods of moving the thumbs of both hands towards the soles of the feet and spinning the laundry are used. The inner and outer parts of the foot are patted in a balanced way. This caressing movement on both feet is done with these movements in a light and rhythmic way and the massage is completed. Data will be obtained with Patient Descriptive Information Form, Vital Signs Follow-up Form, Surgical Anxiety Scale for Adult Patients, Perianesthesia Comfort Scale, Numerical Pain Scale.
Study NCT05146063 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Take the patient's subcutaneous fat tissue to detect the expression of LNK
Description: Take the patient's subcutaneous fat tissue to detect the mRNA and protein expression levels of LNK by RT-qPCR and western blot.
Study NCT05137535 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Family-based questionnaire
Study NCT04875312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound cavitation in group A
Description: Group A:~twenty obese infertile patients with PCO who will be treated by ultrasound cavitation, 2 times per week for 3 months with medical treatment and hypocaloric diet (1200 kcal/day)
Study NCT04875312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electro acupuncture in group B
Description: Group B:~twenty obese infertile patients with PCO who will be treated by electroacupuncture, 3 times per week for 3 months with medical treatment and hypocaloric diet (1200 kcal/day)
Study NCT05790187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Presentation of differents face pictures
Description: Test 1: Unmasked face vs. masked face Test 2: Unmasked face up vs. unmasked face down Test 3: Face masked right side vs. face masked reverse
Study NCT06186726 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: carbon ion radiotherapy
Description: The patients received 72GyE/18 doses of carbon ion radiotherapy.
Study NCT06460181 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Astaxanthin
Description: Manufactured by AstaReal Inc
Study NCT06460181 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Manufactured by AstaReal Inc
Study NCT06173804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted Look Ahead Lifestyle Intervention
Description: Participants will be educated about improving healthy lifestyles involving physical activity and healthy eating to improve physical function and improve glycemic control.
Study NCT05215418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521
Description: Phentermine/Topiramate Top Dose 15 mg/92 mg capsule
Study NCT05215418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phentermine
Description: Phentermine 30 mg capsule
Study NCT05215418 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive oral capsule
Study NCT02205723 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Asthma teaching in ER
Description: Asthma teaching
Study NCT02205723 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma teaching in ER
Description: Asthma teaching
Study NCT02205723 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone Asthma Control
Description: Smartphone Asthma Control
Study NCT04809168 — intervention group
Intervention type: OTHER
Intervention: Questionnaires and inventories
Description: questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed.
Study NCT04675762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Patients randomized to fingolimod will also receive fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is about one hour prior to mechanical thrombectomy.
Study NCT04675762 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized to fingolimod will also receive placebo once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is about one hour prior to mechanical thrombectomy.
Study NCT05524415 — intervention group
Intervention type: DEVICE
Intervention: Neurosteer EEG recorder
Description: The system is composed of hardware and software modules that facilitate the capture and interpretation of electrophysiological data as well as enable viewing the processed data in real time and offline. An electrode patch is attached on the subject's forehead to capture the electrophysiological signal. The signal is sent via low energy Bluetooth to an EEG Monitor. The signal is then sent via Wi-Fi to the cloud where the data is stored on a HIPAA compliant server. Data analysis performed in the cloud transforms the electrophysiological signal into easily readable data of brain activity.
Study NCT04772313 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegloticase
Description: Participants will receive pegloticase with MTX for up to 24 weeks during the treatment period. Participants may opt to receive pegloticase with MTX for an additional 24 weeks.
Study NCT04772313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: Participants will receive MTX during the run-in period then pegloticase with MTX for up to 24 weeks during the treatment period. Participants may opt to receive pegloticase with MTX for an additional 24 weeks.
Study NCT05645744 — intervention group
Intervention type: BIOLOGICAL
Intervention: Prior MB-102 CAR-T cell investigational product.
Description: No investigational product will be administered.
Study NCT05645744 — intervention group
Intervention type: BIOLOGICAL
Intervention: Prior MB-106 CAR-T cell investigational product.
Description: No investigational product will be administered.